Shares of Axon Enterprise, Inc. (NASDAQ:AXON – Get Free Report) have been given a consensus recommendation of “Moderate Buy” by the fourteen research firms that are currently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, two have issued a hold rating and eleven have given a buy rating to the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $604.67.
A number of analysts have recently weighed in on the stock. JMP Securities restated an “outperform” rating on shares of Axon Enterprise in a research note on Tuesday, February 4th. Needham & Company LLC restated a “buy” rating and set a $600.00 price target on shares of Axon Enterprise in a report on Wednesday, February 26th. The Goldman Sachs Group raised their price target on Axon Enterprise from $500.00 to $700.00 and gave the company a “buy” rating in a research report on Monday, January 27th. Northcoast Research cut Axon Enterprise from a “buy” rating to a “neutral” rating in a research report on Wednesday, February 19th. Finally, Barclays restated a “hold” rating on shares of Axon Enterprise in a research report on Monday, March 10th.
Insiders Place Their Bets
Institutional Investors Weigh In On Axon Enterprise
Hedge funds have recently bought and sold shares of the company. Friedenthal Financial grew its stake in Axon Enterprise by 961.7% in the fourth quarter. Friedenthal Financial now owns 1,359 shares of the biotechnology company’s stock valued at $808,000 after acquiring an additional 1,231 shares during the period. Principal Financial Group Inc. grew its position in shares of Axon Enterprise by 33.1% in the 3rd quarter. Principal Financial Group Inc. now owns 136,302 shares of the biotechnology company’s stock valued at $54,466,000 after purchasing an additional 33,869 shares during the period. Artemis Investment Management LLP grew its position in shares of Axon Enterprise by 21.4% in the 4th quarter. Artemis Investment Management LLP now owns 95,113 shares of the biotechnology company’s stock valued at $56,528,000 after purchasing an additional 16,792 shares during the period. Decker Retirement Planning Inc. bought a new stake in shares of Axon Enterprise during the fourth quarter worth $2,985,000. Finally, Geode Capital Management LLC grew its holdings in shares of Axon Enterprise by 2.0% during the third quarter. Geode Capital Management LLC now owns 1,782,828 shares of the biotechnology company’s stock worth $710,103,000 after buying an additional 35,320 shares in the last quarter. 79.08% of the stock is currently owned by institutional investors and hedge funds.
Axon Enterprise Stock Up 11.1 %
Shares of AXON stock opened at $559.84 on Thursday. The company has a market capitalization of $42.90 billion, a price-to-earnings ratio of 144.66, a PEG ratio of 5.17 and a beta of 1.13. The company has a debt-to-equity ratio of 0.32, a quick ratio of 2.63 and a current ratio of 2.96. The stock’s 50 day simple moving average is $571.11 and its 200 day simple moving average is $558.24. Axon Enterprise has a twelve month low of $273.52 and a twelve month high of $715.99.
About Axon Enterprise
Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.
Read More
- Five stocks we like better than Axon Enterprise
- Health Care Stocks Explained: Why You Might Want to Invest
- Quantum Computing: The $6.5 Billion Opportunity You Can’t Ignore
- What is the S&P 500 and How It is Distinct from Other Indexes
- Are Tariffs Threatening Disney’s Comeback Story?
- 5 discounted opportunities for dividend growth investors
- Is Alphabet a Generational Buying Opportunity at These Levels?
Receive News & Ratings for Axon Enterprise Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axon Enterprise and related companies with MarketBeat.com's FREE daily email newsletter.